Efficacy of Ericksonian Hypnosis in the Management of Chronic Pain Related to Parkinson's Disease

Efficacy of Ericksonian Hypnosis in the Management of Chronic Pain Related to Parkinson's Disease

This study evaluates the efficacity of Erickson hypnosis in the treatment of chronic pain in patients with Parkinson's disease. Half of participants will follow a 2-month Erickson hypnosis protocole, while the other half will benefit from the usual care.

A large proportion of patients with Parkinson's disease suffer of chronic pain directly related to the disease. The management of painful symptoms is difficult and currently, there is no commonly admitted guidelines.

Several studies have shown the efficacy of Erickson hypnosis to reduce the perception of chronic pain in different conditions. This efficacy has never been tested in Parkinson's disease.

The objective of this study is to assess the efficacy of Erickson hypnosis protocol, compared to usual care, for the management of Parkinson's disease-related chronic pain.

The study team assume that Erickson hypnosis will be more efficient than usual care to reduce perceived chronic pain. They also assume that regular practice of autohypnosis will contribute to long-term efficacy.

Inclusion Criteria:

• Men or women
• 18 to 80 years old
• idiopathic Parkinson's disease
• without neurological co-morbidity
• Suffering from chronic pain (for at least 3 months), related to Parkinson's disease
• Having a pain intensity of at least 30 mm on the VAS (average intensity over the previous week) for Parkinson's disease-related pain
• antiparkinsonian, analgesic and psychotropic treatments stable for 1-month
• having a health insurance
• signed informed consent form

Exclusion Criteria:

• Patient with a neurological condition other than Parkinson's disease or with an atypical Parkinson's syndrome
• Early untreated patient
• Patient with acute intercurrent pain
• Patient whose pain is mainly attributable to another pathology (rheumatoid arthritis, spondyloarthritis ankylosing, diabetic neuropathy, cancer, etc.)
• Patient with cognitive impairment objectified by a score at the Montreal Cognitive Assessment (MoCA) <24
• Patient with hallucinations and/or psychosis (MDS-UPDRS 1.2> 1)
• Patient with a apathy (MDS-UPDRS 1.5> 1)
• Patient with disabling dyskinesia (MDS-UPDRS) 4.1 AND 4.2> 1)
• Patient under the protection of adults
• Pregnant or lactating woman